Early Breast Cancer
Conditions
Interventions
Intervention group: the patients use the medical wig formulated with sericin during 36 weeks from the start of an anticancer agent
Control group: the patients use the medical wig during 36 weeks from
Sponsors
Graduate School of Medicine, The University of Tokyo
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Early breast cancer patient 2. The patient receive the first anti-cancer drug therapy
Exclusion criteria
Exclusion criteria: 1. The patient with alopecia 2. The patient with scalp dermatitis 3. The patient who cannot answer the questionnaire
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of dermatitis on the scalp (3 weeks later, 12 weeks later, 21 weeks later, 36 weeks later) QOL(3 weeks later, 12 weeks later, 21 weeks later, 36 weeks later) | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of scalp symptoms Scalp barrier functions Time of assessment: 3 weeks later, 12 weeks later, 21 weeks later, 36 weeks later | — |
Countries
Japan
Contacts
Public ContactNao Tamai
Graduate School of Medicine, The University of Tokyo Department of Gerontological Nursing/Wound Care Management, Division of Health Science and Nursing
Outcome results
None listed